MedTrace Logo

Venlafaxine Augmentation in Treatment Resistant Depression

NCT00253266 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2015-04-08

No results posted yet for this study

Summary

This is an assessment of the efficacy of venlafaxine-HCL augmentation with the neuroleptic quetiapine in treatment resistant depression.

Conditions

Interventions

DRUG

Venlafaxine

Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)

DRUG

Quetiapine

Quetiapine up to 200 mg/d for four weeks

Sponsors & Collaborators

  • Max-Planck-Institute of Psychiatry

    lead OTHER

Principal Investigators

  • Florian Holsboer, MD, PhD · Max-Planck-Institute of Psychiatry

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2014-04-30
Completion
2014-08-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00253266 on ClinicalTrials.gov